Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Oct 15;93(21). pii: e00968-19. doi: 10.1128/JVI.00968-19. Print 2019 Nov 1. No abstract available.

2.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.

Lancet HIV. 2019 Oct 7. pii: S2352-3018(19)30262-0. doi: 10.1016/S2352-3018(19)30262-0. [Epub ahead of print]

3.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team, Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD.

J Clin Invest. 2019 Oct 7. pii: 126391. doi: 10.1172/JCI126391. [Epub ahead of print]

4.

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.

Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, Tieu HV, Maenza J, Norwood A, Kobie J, Sinangil F, Pantaleo G, Ding S, McElrath MJ, De Rosa SC, Montefiori DC, Ferrari G, Tomaras GD, Keefer MC; HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network.

J Clin Invest. 2019 Sep 30. pii: 128699. doi: 10.1172/JCI128699. [Epub ahead of print]

5.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
6.

Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques.

Abdulhaqq SA, Martinez M, Kang G, Rodriguez IV, Nichols SM, Beaumont D, Joseph J, Azzoni L, Yin X, Wise M, Weiner D, Liu Q, Foulkes A, Münch J, Kirchhoff F, Coutifaris C, Tomaras GD, Sariol C, Marx PA, Li Q, Kraiselburd EN, Montaner LJ.

Nat Commun. 2019 Aug 21;10(1):3753. doi: 10.1038/s41467-019-11814-5.

7.

Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.

J Virol. 2019 Oct 15;93(21). pii: e02041-18. doi: 10.1128/JVI.02041-18. Print 2019 Nov 1.

PMID:
31434737
8.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, Bennett C, Mayer B, Seaton KE, Yates NL, Baden LR, deCamp AC, Ackerman ME, Seaman MS, Tomaras GD, Nussenzweig MC, Caskey M.

PLoS One. 2019 Aug 8;14(8):e0219142. doi: 10.1371/journal.pone.0219142. eCollection 2019.

9.

Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity.

Kerwin BA, Bennett C, Brodsky Y, Clark R, Floyd JA, Gillespie A, Mayer BT, McClure M, Siska C, Seaman MS, Seaton KE, Shaver J, Tomaras GD, Yates NL, Ketchem RR.

J Pharm Sci. 2019 Jul 23. pii: S0022-3549(19)30444-7. doi: 10.1016/j.xphs.2019.07.009. [Epub ahead of print]

10.

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Nyanhete TE, Frisbee AL, Bradley T, Faison WJ, Robins E, Payne T, Freel SA, Sawant S, Weinhold KJ, Wiehe K, Haynes BF, Ferrari G, Li QJ, Moody MA, Tomaras GD.

Sci Rep. 2019 Jul 15;9(1):10165. doi: 10.1038/s41598-019-46462-8.

11.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO.

Nat Commun. 2019 Jul 1;10(1):2898. doi: 10.1038/s41467-019-10899-2.

12.

Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Pittala S, Bagley K, Schwartz JA, Brown EP, Weiner JA, Prado IJ, Zhang W, Xu R, Ota-Setlik A, Pal R, Shen X, Beck C, Ferrari G, Lewis GK, LaBranche CC, Montefiori DC, Tomaras GD, Alter G, Roederer M, Fouts TR, Ackerman ME, Bailey-Kellogg C.

Mol Syst Biol. 2019 May 2;15(5):e8747. doi: 10.15252/msb.20188747.

13.

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.

Pollara J, Jones DI, Huffman T, Edwards RW, Dennis M, Li SH, Jha S, Goodman D, Kumar A, LaBranche CC, Montefiori DC, Fouda GG, Hope TJ, Tomaras GD, Staats HF, Ferrari G, Permar SR.

J Virol. 2019 May 1;93(10). pii: e02119-18. doi: 10.1128/JVI.02119-18. Print 2019 May 15.

14.

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine.

Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre F, Cameron M, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Rerks-Ngarm S, Kim JH, Thomas R, Gilbert PB, Tomaras GD, Koup RA, Michael NL, McElrath MJ, Gottardo R, Sékaly RP.

Nat Commun. 2019 Feb 20;10(1):863. doi: 10.1038/s41467-019-08854-2.

15.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.

Jones AT, Shen X, Walter KL, LaBranche CC, Wyatt LS, Tomaras GD, Montefiori DC, Moss B, Barouch DH, Clements JD, Kozlowski PA, Varadarajan R, Amara RR.

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.

16.

Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.

Sui Y, Lewis GK, Wang Y, Berckmueller K, Frey B, Dzutsev A, Vargas-Inchaustegui D, Mohanram V, Musich T, Shen X, DeVico A, Fouts T, Venzon D, Kirk J, Waters RC, Talton J, Klinman D, Clements J, Tomaras GD, Franchini G, Robert-Guroff M, Trinchieri G, Gallo RC, Berzofsky JA.

J Clin Invest. 2019 Mar 1;129(3):1314-1328. doi: 10.1172/JCI122110. Epub 2019 Feb 18.

17.

Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.

Tay MZ, Kunz EL, Deal A, Zhang L, Seaton KE, Rountree W, Eudailey JA, Heptinstall J, McRaven MD, Matias E, McGuire E, Yates NL, Perez LG, Montefiori DC, Overman RG, Hope TJ, Shen X, Kalilani L, Fouda GG, Tomaras GD, Permar SR.

J Virol. 2019 Mar 21;93(7). pii: e02084-18. doi: 10.1128/JVI.02084-18. Print 2019 Apr 1.

18.

Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.

Westling T, Juraska M, Seaton KE, Tomaras GD, Gilbert PB, Janes H.

Stat Methods Med Res. 2019 Jan 9:962280218820881. doi: 10.1177/0962280218820881. [Epub ahead of print]

PMID:
30623732
19.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Spearman P, Tomaras GD, Montefiori DC, Huang Y, Elizaga ML, Ferrari G, Alam SM, Isaacs A, Ahmed H, Hural J, McElrath MJ, Ouedraogo L, Pensiero M, Butler C, Kalams SA, Overton ET, Barnett SW; HVTN 088 Protocol Team and the NIH/NIAID HIV Vaccine Trials Network.

J Infect Dis. 2019 May 5;219(11):1755-1765. doi: 10.1093/infdis/jiz008.

PMID:
30615119
20.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R.

J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.

21.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1. Erratum in: J Virol. 2019 Oct 15;93(21):.

22.

CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control.

Nyanhete T, Tomaras GD.

AIDS. 2018 Nov 28;32(18):2835-2838. doi: 10.1097/QAD.0000000000002008. No abstract available.

PMID:
30407253
23.

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.

Blasi M, Negri D, LaBranche C, Alam SM, Baker EJ, Brunner EC, Gladden MA, Michelini Z, Vandergrift NA, Wiehe KJ, Parks R, Shen X, Bonsignori M, Tomaras GD, Ferrari G, Montefiori DC, Santra S, Haynes BF, Moody MA, Cara A, Klotman ME.

Commun Biol. 2018 Sep 5;1:134. doi: 10.1038/s42003-018-0131-6. eCollection 2018.

24.

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses.

Bradley T, Peppa D, Pedroza-Pacheco I, Li D, Cain DW, Henao R, Venkat V, Hora B, Chen Y, Vandergrift NA, Overman RG, Edwards RW, Woods CW, Tomaras GD, Ferrari G, Ginsburg GS, Connors M, Cohen MS, Moody MA, Borrow P, Haynes BF.

Cell. 2018 Oct 4;175(2):387-399.e17. doi: 10.1016/j.cell.2018.08.064. Epub 2018 Sep 27.

25.

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS, Fätkenheuer G, Caskey M, Klein F, Nussenzweig MC.

Nat Med. 2018 Nov;24(11):1701-1707. doi: 10.1038/s41591-018-0186-4. Epub 2018 Sep 26.

26.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu CL, Handl L, Unson-O'Brien C, Patel R, Ruping C, Schlotz M, Witmer-Pack M, Shimeliovich I, Kremer G, Thomas E, Seaton KE, Horowitz J, West AP Jr, Bjorkman PJ, Tomaras GD, Gulick RM, Pfeifer N, Fätkenheuer G, Seaman MS, Klein F, Caskey M, Nussenzweig MC.

Nature. 2018 Sep;561(7724):479-484. doi: 10.1038/s41586-018-0531-2. Epub 2018 Sep 26.

27.

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.

Ackerman ME, Das J, Pittala S, Broge T, Linde C, Suscovich TJ, Brown EP, Bradley T, Natarajan H, Lin S, Sassic JK, O'Keefe S, Mehta N, Goodman D, Sips M, Weiner JA, Tomaras GD, Haynes BF, Lauffenburger DA, Bailey-Kellogg C, Roederer M, Alter G.

Nat Med. 2018 Oct;24(10):1590-1598. doi: 10.1038/s41591-018-0161-0. Epub 2018 Sep 3.

28.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

29.

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.

Dennison SM, Reichartz M, Seaton KE, Dutta S, Wille-Reece U, Hill AVS, Ewer KJ, Rountree W, Sarzotti-Kelsoe M, Ozaki DA, Alam SM, Tomaras GD.

J Immunol. 2018 Aug 15;201(4):1315-1326. doi: 10.4049/jimmunol.1800323. Epub 2018 Jul 13.

30.

Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection.

Vaidya NK, Ribeiro RM, Liu P, Haynes BF, Tomaras GD, Perelson AS.

Front Microbiol. 2018 Jun 20;9:1326. doi: 10.3389/fmicb.2018.01326. eCollection 2018.

31.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

32.

Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Singh S, Ramírez-Salazar EG, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, Hamlin C, Rao M, Dayton F, Bear J, Chowdhury B, Alicea C, Lifson JD, Broderick KE, Sardesai NY, Sivananthan SJ, Fox CB, Reed SG, Venzon DJ, Hirsch VM, Pavlakis GN, Felber BK.

J Virol. 2018 Jul 17;92(15). pii: e00281-18. doi: 10.1128/JVI.00281-18. Print 2018 Aug 1.

33.

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.

Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G.

Nat Med. 2018 Jun;24(6):847-856. doi: 10.1038/s41591-018-0025-7. Epub 2018 May 21.

34.

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.

Schiffner T, Pallesen J, Russell RA, Dodd J, de Val N, LaBranche CC, Montefiori D, Tomaras GD, Shen X, Harris SL, Moghaddam AE, Kalyuzhniy O, Sanders RW, McCoy LE, Moore JP, Ward AB, Sattentau QJ.

PLoS Pathog. 2018 May 10;14(5):e1006986. doi: 10.1371/journal.ppat.1006986. eCollection 2018 May.

35.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

36.

Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.

Pollara J, Orlandi C, Beck C, Edwards RW, Hu Y, Liu S, Wang S, Koup RA, Denny TN, Lu S, Tomaras GD, DeVico A, Lewis GK, Ferrari G.

Cytometry A. 2018 Apr;93(4):436-447. doi: 10.1002/cyto.a.23348. Epub 2018 Mar 2.

37.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.

Saunders KO, Santra S, Parks R, Yates NL, Sutherland LL, Scearce RM, Balachandran H, Bradley T, Goodman D, Eaton A, Stanfield-Oakley SA, Tartaglia J, Phogat S, Pantaleo G, Esteban M, Gomez CE, Perdiguero B, Jacobs B, Kibler K, Korber B, Montefiori DC, Ferrari G, Vandergrift N, Liao HX, Tomaras GD, Haynes BF.

J Virol. 2018 Mar 28;92(8). pii: e02035-17. doi: 10.1128/JVI.02035-17. Print 2018 Apr 15.

38.

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD.

J Virol. 2018 Mar 28;92(8). pii: e01843-17. doi: 10.1128/JVI.01843-17. Print 2018 Apr 15.

39.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

40.

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.

Wills S, Hwang KK, Liu P, Dennison SM, Tay MZ, Shen X, Pollara J, Lucas JT, Parks R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Thomas R, Kim JH, Michael NL, Robb ML, McRaven M, Montefiori DC, Hope TJ, Liao HX, Moody MA, Ferrari G, Haynes BF, Alam SM, Bonsignori M, Tomaras GD.

J Virol. 2018 Mar 14;92(7). pii: e01552-17. doi: 10.1128/JVI.01552-17. Print 2018 Apr 1.

41.

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, Valiante NM, Malyala P, Barnett SW, Sarkar P, Singh M, Jain S, Ackerman M, Alam M, Ferrari G, Salazar A, Tomaras GD, O'Hagan DT, Aderem A, Alter G, Seder RA.

Blood Adv. 2017 Nov 17;1(25):2329-2342. doi: 10.1182/bloodadvances.2017011411. eCollection 2017 Nov 28. Erratum in: Blood Adv. 2018 Mar 13;2(5):516.

42.

Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, Housman M, Bouton-Verville H, Shen X, Trama AM, Scearce R, Sutherland L, Santra S, Newman A, Eaton A, Xu K, Georgiev IS, Joyce MG, Tomaras GD, Bonsignori M, Reed SG, Salazar A, Mascola JR, Moody MA, Cain DW, Centlivre M, Zurawski S, Zurawski G, Erickson HP, Kwong PD, Alam SM, Levy Y, Montefiori DC, Haynes BF.

Cell Rep. 2017 Dec 26;21(13):3681-3690. doi: 10.1016/j.celrep.2017.12.028.

43.

Computational analysis of antibody dynamics identifies recent HIV-1 infection.

Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao HX, Haynes BF, Robb ML, Parkin N, Santos BR, Garrett N, Price MA, Naniche D, Duerr AC; CEPHIA group, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher CD, Cohen MS, Tomaras GD.

JCI Insight. 2017 Dec 21;2(24). pii: 94355. doi: 10.1172/jci.insight.94355.

44.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.

Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.

J Virol. 2018 Feb 12;92(5). pii: e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.

45.

Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies.

Ramesh A, Darko S, Hua A, Overman G, Ransier A, Francica JR, Trama A, Tomaras GD, Haynes BF, Douek DC, Kepler TB.

Front Immunol. 2017 Oct 27;8:1407. doi: 10.3389/fimmu.2017.01407. eCollection 2017.

46.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

47.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

48.

HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.

McGuire EP, Fong Y, Toote C, Cunningham CK, McFarland EJ, Borkowsky W, Barnett S, Itell HL, Kumar A, Gray G, McElrath MJ, Tomaras GD, Permar SR, Fouda GG.

J Virol. 2017 Dec 14;92(1). pii: e01070-17. doi: 10.1128/JVI.01070-17. Print 2018 Jan 1.

49.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.

Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, Robinson HL.

J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.

50.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

Supplemental Content

Loading ...
Support Center